skip to Main Content

Medical Countermeasures

Swift, Effective, Flexible

MRIGlobal accelerates the discovery and development of broad-spectrum medical countermeasures to prevent or mitigate the adverse health effects resulting from chemical threat agents, infectious disease, and bioterrorism.

Highly Toxic Materials Medical Countermeasures

  • Chemical Warfare Agents
  • Toxic Industrial Chemicals
  • Emerging Chemical Threats

Biological Medical Countermeasures

  • Emerging Infectious Disease
  • Infectious Disease
  • Biological Warfare
  • Antimicrobial Resistance

Contact

Robert Casillas, Ph.D.
816-401-7783

Request Information

Featured Work

MRIGlobal Leads International Research Collaboration for Tularemia Vaccine

MRIGlobal Leads International Research Collaboration for Tularemia Vaccine

Animal Health

Collaboration includes scientists from Canada, Sweden, U.S. in $6.2 million Defense Threat Reduction Agency contract award. MRIGlobal has been awarded a $6.2 million, 5-year program from the Defense Threat Reduction Agency (DTRA) for the development of a vaccine for tularemia. The award continues a long-standing international co-operation to develop a tularemia vaccine. Tularemia is a disease of animals and humans…

read more

Featured Work

  • Tue
    28
    Nov
    2017
    Thu
    30
    Nov
    2017

    DTRA CBD S&T Conference

    Long Beach, CA

    Long Beach Convention Center, Booth 342
    CLICK HERE

  • Mon
    12
    Feb
    2018
    Wed
    14
    Feb
    2018

    2018 ASM Biothreats: Research, Response, and Policy

    Baltimore, MD
  • Sun
    11
    Mar
    2018
    Thu
    15
    Mar
    2018

    SOT (Society of Toxicology)

    San Antonio, TX
  • Thu
    07
    Jun
    2018
    Mon
    11
    Jun
    2018

    ASM Microbe Hospitality Event

    Atlanta, Georgia

Unique Facilities and Offerings

Chemical Medical Countermeasures

Seamless collaboration with Government, Industry, Academia to provide support for the development of medical countermeasures against chemical threat agents including:

  • Nerve agents
  • Blister agents
  • Lung damaging agents
  • Toxic Industrial Chemicals/Materials (TICs/TIMs)
  • Pesticides
  • DHS CTRA Threat List Agents
  • More than 276 linear feet of hood capacity (twice that of the leading competitor)
  • Highly secure Chemical Containment and Animal Exposure facilities
  • Unrestricted access to DoD and non-DoD chemical agents
  • Technical staff with extensive experience in SOP development, safety, ISO and GLP procedure
  • Ocular
    • Skin
    • Animal Models of Exposure (liquid or vapor)
    • Lung – Intratracheal or inhalation
    • Parenteral
  •  In vivo Safety and Efficacy Studies
    • Inhalation, intranasal, Dermal, Intramuscular, Intravenous, Intraperitoneal, and Subcutaneous routes of exposure
  • Animal model development
    • Plethysmography/Spirometry
    • Telemetry and Physiology
  • Assay Development And Validation
  • Pharmacokinetics
    • PK Assay Development
    • Dose-ranging Studies
  • Safety Studies
  • Histology and Pathology
  • Blood Chemistry and Hematology Studies
  • Customized study designs and alternative animal models
  • Biomarkers of toxicity
    • Cholinesterase inhibition
  • Cell-based Toxicity Assays
  • Cytotoxicity (high throughput)
  • Transcriptomics/Proteomics
  • Metabolomics

Biological Medical Countermeasures

Research and development, clinical testing, safety assessments, and support for regulatory approvals and commercialization of products for improving human health, and where applicable, in compliance with FDA “Animal Rule” (21 CFR Part 314).

Toxicology staff are enrolled in the MRIGlobal Biological Personnel Reliability Program (BPRP) and/or certified by the U.S. Army Chemical Personnel Reliability Program (CPRP).

  • Category A,B,& C Bacterial Pathogens
  • Foodborne Bacterial Pathogens
  • Multi-Drug Resistance (MDR) and Pathogens
  • Other Tier 1 HHS and USDA Select Agents and Toxins
More than 35 years of experience working with viruses from different families and genera. Complete services in assay development, biodefense, viral culture, decontamination, diagnostics, molecular virology, repository, serology, vaccine development, and other virology support.

Experience specific to influenza virus, including highly pathogenic Avian influenza virus (HPAIV ) Influenza: (H1N1, H5N1, H7N9, H3N2, B), Encephalitis viruses, Hemorrhagic Fever Viruses include:

  • All necessary permits, licensing, and certifications to acquire, maintain, and work with viruses
  • Existing stocks of seasonal, veterinary isolates, reverse genetics reassortants, vaccine, and H5N1 strains
  • Preclinical toxicology to support vaccine development

Experience

  • Evaluation of influenza POC diagnostics, including HPAI
  • Ferret intranasal and bioaerosol challenge studies with H5N1 and H1N1 strain
  • Mouse intranasal challenge with H5N1 and H1N1 strains
  • Egg infectious dose and TCID50 in MDCK, MV1 Lu, and other cells
  • Immunogenicity assays and ELISAs
  • Isolation and titration of virus from infected tissues, organs, nasal washes, feces and rectal swabs
  • Hemagglutination assays using human, guinea pig, horse, chicken, or turkey cells
  • Hemagglutination inhibition assays using human or animal sera

Isolation, Culture, and Evaluation

  • Human and animal influenza viruses (including highly pathogenic avian influenza virus)
  • Food-borne and water-borne viruses (including enteroviruses)
  • Anthropod-borne viruses (including West Nile Virus)
  • CDC select agents (including the encephalitic alphaviruses and flaviviruses)
  • Prion protein production (including hamster adapted scrapie strain 263K)
  • Virus simulants (including empty capsid particles and alphavirus replicons)
  • Development and maintenance of repositories
  • Large scale production in static and suspension cultures
  • Serology work including development and validation of ELISAs
  • Microneutralization and plaque reduction neutralization assays
  • Aerosol inhalation studies for various animal models including ferrets

Molecular Support

  • Genomic sequencing of known and newly discovered RNA and DNA viruses (Including examples: GenBank Access # EF568607, EF571853, EF571854, EU081844)
  • PCR assay design, development and validation, including reverse-transcriptase and real-time PCR assays
  • Full genome cloning of RNA and small DNA viruses

Product Support

  • Human and veterinary vaccine safety and efficacy studies
  • Adventitious agent screening and validation of viral decontamination
  • Viral clearance studies from cell culture derived products
  • Prion clearance studies from plasma products
  • Testing of live vaccine formulations, including pH, osmolality and Karl Fisher Tests)

Basic Research

  • Vaccine design and development
  • Development of animal challenge models (including aerosol exposures)
  • Eukaryotic protein expression from viral vectors
    • Antibody production
  • Selection and characterization of viral mutants
  • Assessment of viral evolution and quasispecies
  • Literature searches and development of expert reviews

Specialized Facilities: Techniplast caging for optimal animal health and collection efficiency plus protection against cross-contamination

Vaccine development for both viral and bacterial pathogens, with focus on Biodefense and Emerging Pathogens or Threats:

  • Animal Models of infection and pre-clinical testing
  • Plaque titers, Virus neutralization
  • Cell-based assays

Evaluation of Drugs and Therapeutics for both Biodefense and Industrial Applications Against Pathogenic Bacteria

  • Infection models and natural histories
  • Minimum Inhibitory Concentration (MIC) CLSI standards
  • In vitro and In vivo Safety Studies
  • Small Molecule and Peptide PK Assays & Analytical Methods
  • In vivo Safety and Efficacy Studies: Inhalation, Intranasal, Dermal, Intramuscular, Intravenous, Intraperitoneal, and Subcutaneous routes of exposure
  • Animal model development: Plethysmography/Spirometry, Telemetry and Physiology
  • Assay Development and Validation: Pharmacokinetics, PK Assay Development, Dose Ranging Studies
  • Safety Studies
  • Histology and Pathology
  • Blood Chemistry & Hematology
  • Certified laboratories at BSL-2, BSL3, ABSL-2, ABSL-3
  • Highly secure facilities, registered with the CDC and USDA for handling Tier 1 HHS and USDA Select Agents and Toxins (7 CFR Part 331, 9 CFR Part 121, and 42 CFR Part 73)
  • Immunoassays: Cytokines, Serology
  • Biomarkers of infection/toxicity
  • Cell Based Assays: Neutralizing Ab, Cytotoxicity
  • Molecular Assays: RTPCR, Next Gen Sequencing

We are different.

MRIGlobal stands apart from other research organizations. We offer both pre/nonclinical studies requiring high containment and relevant in vivo models and routes of exposure.